EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Gabapentin Tablets are indicated for management of postherpetic neuralgia in adults
Department of Biotechnology is going to play an important part in the integrated holistic healthcare approach against elimination of Tuberculosis
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
Subscribe To Our Newsletter & Stay Updated
